Revealing the Impact of Structural Variants in Multiple Myeloma

Even H. Rustad(Memorial Sloan Kettering Cancer Center), Venkata Yellapantula(Memorial Sloan Kettering Cancer Center), Dominik Głodzik(Memorial Sloan Kettering Cancer Center), Kylee Maclachlan(Memorial Sloan Kettering Cancer Center), Benjamin Diamond(Memorial Sloan Kettering Cancer Center), Eileen M. Boyle(NYU Langone Health), Cody Ashby(University of Arkansas Medical Center), Patrick Blaney(NYU Langone Health), Gunes Gundem(Memorial Sloan Kettering Cancer Center), Malin Hultcrantz(Memorial Sloan Kettering Cancer Center), Daniel Leongamornlert(Wellcome Sanger Institute), Nicos Angelopoulos(University of Essex), Luca Agnelli(Fondazione IRCCS Istituto Nazionale dei Tumori), Daniel Auclair(Multiple Myeloma Research Foundation), Yanming Zhang(Memorial Sloan Kettering Cancer Center), Ahmet Doǧan(Memorial Sloan Kettering Cancer Center), Niccolò Bolli(University of Milan), Elli Papaemmanuil(Memorial Sloan Kettering Cancer Center), Kenneth C. Anderson(Dana-Farber Cancer Institute), Philippe Moreau(Centre National de la Recherche Scientifique), Hervé Avet‐Loiseau(Inserm), Nikhil C. Munshi(VA Boston Healthcare System), Jonathan J. Keats(Translational Genomics Research Institute), Peter J. Campbell(Wellcome Sanger Institute), Gareth J. Morgan(NYU Langone Health), Ola Landgren(Memorial Sloan Kettering Cancer Center), Francesco Maura(Memorial Sloan Kettering Cancer Center)
Blood Cancer Discovery
September 15, 2020
Cited by 128Open Access
Full Text

Abstract

Abstract The landscape of structural variants (SV) in multiple myeloma remains poorly understood. Here, we performed comprehensive analysis of SVs in a large cohort of 752 patients with multiple myeloma by low-coverage long-insert whole-genome sequencing. We identified 68 SV hotspots involving 17 new candidate driver genes, including the therapeutic targets BCMA (TNFRSF17), SLAM7, and MCL1. Catastrophic complex rearrangements termed chromothripsis were present in 24% of patients and independently associated with poor clinical outcomes. Templated insertions were the second most frequent complex event (19%), mostly involved in super-enhancer hijacking and activation of oncogenes such as CCND1 and MYC. Importantly, in 31% of patients, two or more seemingly independent putative driver events were caused by a single structural event, demonstrating that the complex genomic landscape of multiple myeloma can be acquired through few key events during tumor evolutionary history. Overall, this study reveals the critical role of SVs in multiple myeloma pathogenesis. Significance: Previous genomic studies in multiple myeloma have largely focused on single-nucleotide variants, recurrent copy-number alterations, and recurrent translocations. Here, we demonstrate the crucial role of SVs and complex events in the development of multiple myeloma and highlight the importance of whole-genome sequencing to decipher its genomic complexity. See related commentary by Bergsagel and Kuehl, p. 221. This article is highlighted in the In This Issue feature, p. 215


Related Papers

No related papers found

Powered by citation graph analysis